Geneva, 28 October 2020 – Gavi, the Vaccine Alliance announced today that it had signed a Statement of Intent with Sanofi and GSK to provide 200 million doses of the companies’ adjuvanted recombinant protein COVID-19 vaccine to the COVAX Facility. The non-binding statement is a critical step toward making sure doses of the vaccine, if approved and licensed, will be made available to all countries and economies participating in the COVAX Facility. 

“The signing of this statement of intent is an important step forward in our partnership, and I welcome Sanofi and GSK’s commitment to the COVAX goal of equitable access to COVID-19 vaccines,” said Seth Berkley, CEO of Gavi. “Gavi is seeking to secure doses of the most promising vaccine candidates – so that the 184 participants involved in the COVAX Facility can make sure their most at-risk groups, such as healthcare workers, have rapid access to doses of a safe and effective vaccine. That is the world’s best chance to end the acute stage of this pandemic, and we encourage other vaccine manufacturers to work with us towards that shared global goal.”

Gavi is coordinating the design and implementation of the COVAX Facility, a global mechanism which seeks to procure, equitably allocate and deliver 2 billion doses of safe and effective COVID-19 vaccines by the end of 2021. 92 higher-income economies have already signed up as self-financing members of the Facility, joining 92 low-and middle-income economies who will have their participation supported by the Gavi COVAX AMC.

The COVAX Facility is part of COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, which is co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance, and the World Health Organization (WHO) – working in partnership with developed and developing country vaccine manufacturers, UNICEF, the World Bank, Civil Society Organisations and others. COVAX is the only global initiative that is working with governments and manufacturers to ensure COVID-19 vaccines are available worldwide to economies of all financial means.

Media Contacts

Meghana Sharafudeen
+41 79 711 5554

Subscribe to our newsletter